<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697446</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-667-2404</org_study_id>
    <nct_id>NCT04697446</nct_id>
  </id_info>
  <brief_title>External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC</brief_title>
  <official_title>An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Analysis Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an external control, observational, retrospective study designed to compare clinical&#xD;
      outcomes for pralsetinib compared with best available therapy for patients with RET-fusion&#xD;
      positive advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparative evaluation of real-world response rate (rwORR) between patients receiving best available therapy versus pralsetinib</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>rwORR, defined as the proportion of patients with clinician-assess complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Overall survival (OS)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>OS, defined as time from initiation of a given line of therapy to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Real-world duration of response (rwDOR)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>rwDOR, defined as the duration of time from the first documented clinician-assessed response to the first documented clinician-assessed progressive disease or death due to any cause within 30 days of the last radiological exam, for each line of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Real-world disease control rate (rwDCR)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>rwDCR, defined as proportion of patients with clinician-assessed complete response, partial response, or stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Real-world clinical benefit rate (rwCBR)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>rwCBR, defined as proportion of patients who had documented clinician-assessed complete response or partial response, or stable disease lasting at least 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Real-world progression-free survival (rwPFS)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>rwPFS, defined as time from initiation of line of therapy to clinician-assessed disease progression or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Duration of treatment (DOT)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>DOT, defined as time from initiation of line of systemic treatment to discontinuation of same line of treatment for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative evaluation between patients receiving best available therapy versus pralsetinib of Time to next treatment line (TtNTL)</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>TtNTL, defined as the time from initiation of line of systemic treatment to the initiation of the next line of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the safety profile and conduct comparative evaluation of safety between patients receiving best available care vs. pralsetinib</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Adverse events (AEs) that result in treatment modification or discontinuation, hospitalization, or death according to evaluation of responsible physician</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">279</enrollment>
  <condition>RET-fusion Non Small Cell Lung Cancer</condition>
  <condition>Lung Neoplasm</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Respiratory Tract Neoplasms</condition>
  <condition>Thoracic Neoplasms</condition>
  <condition>Neoplasms by Site</condition>
  <condition>Neoplasms</condition>
  <condition>Lung Diseases</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Carcinoma, Bronchogenic</condition>
  <condition>Bronchial Diseases</condition>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Carcinoma</condition>
  <condition>Neoplasms by Histologic Type</condition>
  <condition>Neoplasms, Germ Cell and Embryonal</condition>
  <condition>Neoplasms, Nerve Tissue</condition>
  <condition>Metastatic Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Patients from the BLU-667-1101 (ARROW) study</arm_group_label>
    <description>Patients with Non-Small Cell Lung Cancer (NSCLC) who received treatment with pralsetinib as part of the BLU-667-1101 (ARROW) study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External Control Group</arm_group_label>
    <description>Patients with Non-Small Cell Lung Cancer (NSCLC) that received best available therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include patients with locally advanced or metastatic RET-fusion positive&#xD;
        non-small cell lung cancer (NSCLC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a diagnosis of locally advanced (non-resectable) or metastatic RET-fusion&#xD;
             positive NSCLC&#xD;
&#xD;
          -  Must have received at least one line of systemic therapy for locally advanced&#xD;
             (non-resectable) or metastatic RET-fusion positive NSCLC, which may include regimens&#xD;
             containing:&#xD;
&#xD;
               -  Chemotherapy, e.g., regimens containing platinum doublet-based therapy&#xD;
                  (carboplatin, cisplatin)&#xD;
&#xD;
               -  Chemotherapy in combination with other drugs will be assessed, e.g., in&#xD;
                  combination with pemetrexed, immune checkpoint inhibitors (pembrolizumab),&#xD;
                  bevacizumab&#xD;
&#xD;
               -  Ramucirumab in combination with docetaxel&#xD;
&#xD;
               -  Immune checkpoint inhibitors, e.g., pembrolizumab, nivolumab, and atezolizumab&#xD;
&#xD;
               -  MKIs, e.g., cabozantinib, alectinib, vandetanib, sunitinib, and nintedanib&#xD;
&#xD;
          -  Must be aged â‰¥18 years of age at the initiation of first systemic line of therapy&#xD;
&#xD;
          -  Must have availabile of performance status (e.g., Eastern Cooperative Oncology Group&#xD;
             [ECOG] score or Karnofsky score)&#xD;
&#xD;
          -  Must have an index date at least 3 months prior to the start of data collection (in&#xD;
             order to include patients with at least 3 months of follow-up after index date),&#xD;
             unless date of death occurred less than three months from index date&#xD;
&#xD;
          -  Must have an approved waiver of informed consent or signed informed consent for&#xD;
             participation in the retrospective chart review study, as applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known primary driver alteration other than RET (e.g., targetable mutation in EGFR,&#xD;
             ALK, ROS1, or BRAF)&#xD;
&#xD;
          -  History of other malignancy, other than non-melanoma skin cancer, within 1 year prior&#xD;
             to initiation of first systemic therapy&#xD;
&#xD;
          -  Received pralsetinib as the first line of systemic therapy for RET-fusion positive&#xD;
             NSCLC, or prior to initiation of first systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Center of Toulouse - Larrey Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucerne Cantonal Hospital</name>
      <address>
        <city>Lucerne</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Neoplasms by Site</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Thoracic Neoplasms</mesh_term>
    <mesh_term>Respiratory Tract Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Bronchogenic</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
    <mesh_term>Bronchial Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

